Skip to main content
. 2020 Dec 16;80(5):582–590. doi: 10.1136/annrheumdis-2020-218808

Figure 2.

Figure 2

ASAS20 response rates at week 12 (MI). OR secukinumab 300 mg versus placebo: 3.8, p<0.0001 secukinumab 150 mg versus placebo: 4.4, p<0.0001. ASAS, Assessment of SpondyloArthritis International Society; MI, multiple imputation; N, total number of randomised patients (full analysis set); s.c., subcutaneous.